Research

Mixed

Pharmacological clearance of senescent cells using senolytics (specifically dasatinib and quercetin) extends health span and reduces age-related pathologies in mouse models.

This paper describes a preclinical strategy using specific drugs (senolytics) to clear aged cells. It is not a DIY protocol. The findings suggest that targeting cellular aging mechanisms is a viable path for extending health span, but human application requires further clinical trials to establish safety and efficacy.

ModerateSupportsMEDIUM confidence
combination of dasatinib and quercetin reduced SC burden in chronologically aged, radiation-exposed, and Ercc1−/Δ-progeroid mice, which resulted in extension of health span and reduction of age-related pathologies (29).
Eok-Cheon Kim et al. · BMB Reports · 2019

Why this rating

Evidence is derived from multiple animal models (mice) and in vitro studies; no human clinical trial results are reported in this review, only preclinical data.

Source

Senotherapeutics: emerging strategy for healthy aging and age-related disease

Eok-Cheon Kim et al. · BMB Reports · 2019

DOI 10.5483/bmbrep.2019.52.1.293

narrative_reviewCited 199×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →